

NCT01410890 Raw comparison:

Summary:
CHIA has 7 criteria while your personal folder has 11 criteria
Total found criteria: 6/7
Total not Found: 1/7
Total Extra: 4
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ The patient and/or the patient's parent/legal      │ The participant and/or the participant's           │
│ guardian is willing and able to provide signed     │ parent/legal guardian was willing and able to      │
│ informed consent                                   │ provide signed informed consent                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Infant and toddler Pompe disease patients can be   │ Infant and toddler Pompe disease participants      │
│ included in the study only under condition         │ could be included in the study only under          │
│ (minimal body weight) that the trial-related blood │ condition (minimal body weight) that the trial-    │
│ loss (including any losses in the maneuver) will   │ related blood loss (including any losses in the    │
│ not exceed 3 percent of the total blood volume     │ maneuver) would not exceed 3 percent (%) of the    │
│ during a period of 4 weeks and will not exceed 1   │ total blood volume during a period of 4 weeks and  │
│ percent at any single time                         │ would not exceed 1 % at any single time            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient if female and of childbearing          │ The participant if female and of childbearing      │
│ potential must have a negative pregnancy test      │ potential must have had a negative pregnancy test  │
│ (urine beta-human chorionic gonadotropin) at       │ (urine beta-human chorionic gonadotropin) at       │
│ screening Note All female patients of childbearing │ screening Note All female participants of          │
│ potential and sexually mature males must agree to  │ childbearing potential and sexually mature males   │
│ use a medically accepted method of contraception   │ must have agreed to use a medically accepted       │
│ throughout the study                               │ method of contraception throughout the study       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For patients previously treated with alglucosidase │ For participants previously treated with           │
│ alfa the patient has received alglucosidase alfa   │ alglucosidase alfa the participant had received    │
│ for at least 6 months                              │ alglucosidase alfa for at least 6 months           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient is participating in another clinical   │ The participant was participating in another       │
│ study using an investigational product             │ clinical study using an investigational product    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient in the opinion of the Investigator is  │ The participant in the opinion of the Investigator │
│ unable to adhere to the requirements of the study  │ was unable to adhere to the requirements of the    │
│                                                    │ study                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                         │
╞═════════════════════════════════════════════════════════════════════════════════════════════╡
│ The patient has a confirmed GAA enzyme deficiency from skin blood or muscle tissue and/or 2 │
│ confirmed GAA gene mutations                                                                │
╘═════════════════════════════════════════════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                           │
╞═══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ The above information was not intended to contain all considerations relevant to a participant's  │
│ potential participation in a clinical trial                                                       │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A participant who met any of the following criteria was excluded from this study                  │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ The participant had a confirmed acid alpha-glucosidase (GAA) enzyme deficiency from skin blood or │
│ muscle tissue and/or 2 confirmed GAA gene mutations                                               │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A participant was to meet all of the following criteria to be eligible for this study             │
╘═══════════════════════════════════════════════════════════════════════════════════════════════════╛